졸피뎀타르트레이트

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H302：삼키면 유해함

  H411：장기적 영향에 의해 수생생물에 유독함

• 예방조치문구

  P264：취급 후에는 손을 철저히 씻으시오.

  P264：취급 후에는 손을 철저히 씻으시오.

  P270：이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.

  P301+P312：삼켜서 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.

  P330：입을 씻어내시오.

  P501：...에 내용물 / 용기를 폐기 하시오.

졸피뎀타르트레이트 화학적 특성, 용도, 생산

• 화학적 성질

  White or almost white, hygroscopic, crystalline powder.

• 용도

  Sedativehypnotic.

• 정의

  ChEBI: The hemitartrate salt of zolpidem.

• Pharmacokinetics

  Zolpidem exhibits a high selectivity for the α1 subunit. Its good bioavailability of 72% and rapid onset of action of approximately 1.4 hours following oral absorption can be attributed to its weak base (pKa = 6.2) and high lipophilicity (mlog P = 3.85). Its pharmacokinetic profile is characterized by rapid absorption from the gastrointestinal tract and a short elimination half-life because of rapid oxidative metabolism to inactive carboxylic acid metabolites. Zolpidem undergoes CYP3A4 (major), CYP2DG, and CYP2D6 hydroxylation of the aryl methyl groups, followed by further oxidation by aldehyde dehydrogenase to the ionic carboxylic acids, which are readily eliminated in the urine.
  Zolpidem demonstrates linear (dose-proportional) kinetics in the dose range of 5 to 20 mg. Although protein binding was 90%, no drug accumulation was observed following nightly dosing with 20-mg zolpidem tartrate tablets for 2 weeks. Food can prolong the time to peak concentration from 1.4 to 2.2 hours without affecting the half-life. These results suggest that for faster sleep onset, zolpidem should not be administered with or immediately after a meal. In the elderly, the dose should be 5 mg, because the elimination half-life is increased by 50% (from ~2 to ~3 hours). No accumulation was observed in elderly subjects following nightly oral dosing of 10 mg for 1 week. In patients with hepatic insufficiency, the plasma concentration doubled with an increase in the elimination half-life from approximately 2 to approximately 10 hours (range, 4–25 hours). Therefore, dosing should be modified in patients with hepatic insufficiency. No dosage adjustment should be necessary in patients with compromised renal function. Zolpidem is not hemodialyzable, but it does cross the placenta and into breast milk. Because of its longer elimination half-life (when compared to zaleplon), it may be preferred when sleep maintenance is a primary concern.

졸피뎀타르트레이트 준비 용품 및 원자재

졸피뎀타르트레이트 공급 업체

Global(170)Suppliers

졸피뎀타르트레이트 관련 검색